{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-090461","form_type":"8-K","ticker":"DRIO","cik":"0001533998","company_name":"DarioHealth Corp.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.060384+00:00","generated_at":"2026-06-23T23:49:50.326176+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DarioHealth Q2 revenue $6.2M (+17.5% YoY); net loss $18M; strategic shift to B2B2C","bullets":["Q2 revenue $6.2M, up 17.5% YoY but down 23.3% sequentially; gross margin 18.4% (pro-forma 36.1%).","Net loss $18.0M vs $17.8M in Q2 2021; operating loss $17.4M; cash $68M.","B2B2C contract value totals $55M; new national health plan deal providing reach to ~10M members.","Strategic decision to reduce DTC focus and prioritize B2B2C channels, cutting customer acquisition costs 70%.","Secured up to $50M non-dilutive credit facility with OrbiMed; on track to exceed 100 B2B2C contracts by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-090461","json":"https://secwatch.observer/filing/0001104659-22-090461.json","markdown":"https://secwatch.observer/filing/0001104659-22-090461.md","text":"https://secwatch.observer/filing/0001104659-22-090461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533998/000110465922090461/0001104659-22-090461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533998/000110465922090461/tm2223436d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:49:50.326176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}